69 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
, responsible for the global clinical development of sorafenib (Nexavar ® ) at Bayer. Former CEO of PROLOR Biotech. Founding team and Director of R&D
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
financial statements include the accounts of the Company and Enlivex Therapeutics R&D Ltd. and Enlivex Therapeutics RDO Ltd., its wholly owned subsidiaries … to operate in the foreseeable future. The functional currency of Enlivex Therapeutics R&D Ltd. was the New Israeli Shekel (“NIS”) until September 30
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
in salaries as a result of hiring additional R&D personnel and certain pay increases for existing R&D personnel .
General and administrative expenses … manufactured and inventoried, as well as from an increase in salaries as a result of hiring additional R&D personnel and certain pay increases for existing R
6-K
EX-99.1
knrgt7xptnnzgbj6l
31 Mar 23
Report of Foreign Private Issuer
4:30pm
424B5
uocsi
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
faunu62q3j
5 Dec 22
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
8:05am
6-K
EX-99.1
fhvxys2
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
fdjy36 6xlhgp
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
81gb6q6l3zv5hjoj4uks
24 Aug 22
Report of Foreign Private Issuer
8:05am
6-K
EX-99.1
nas d6h84d
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.2
6fowdcvu pyvoeuhe9
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.3
y2br8q
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.1
lxkn6rbm
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.2
9sgdtah0m5 k2hy
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.1
8bw d474gektni7
29 Apr 22
Report of Foreign Private Issuer
8:15am
F-3
lcn94rdpa 7zf
29 Apr 22
Shelf registration (foreign)
8:14am